镰状细胞病造血干细胞移植后风湿性心肌病逆转
该研究纳入56例接受HSCT的镰状细胞病患者(41例HLA相合,15例单倍体相合),其中32例在移植前3个月内接受红细胞置换。结果显示成功HSCT后3个月心脏大小、功能和舒张充盈参数显著改善,并持续至1年,NT-proBNP显著改善,6分钟步行时间有改善趋势。
要点
- HSCT后3个月心脏结构、功能及舒张充盈参数显著改善,持续至1年。
- HSCT后1年NT-proBNP显著改善,6分钟步行时间有改善趋势。
- RBCx虽改善溶血和贫血,但左心室容积指数轻度增加。
核心结论
- 成功HSCT后镰状细胞病患者的心脏大小、功能和舒张充盈参数显著改善,并持续至1年。
研究设计与样本
- 研究纳入56例接受HSCT的镰状细胞病患者,其中41例HLA相合、15例单倍体相合,32例在HSCT前3个月内接受RBCx。
- 在基线及HSCT后3、6、12个月获取超声心动图和实验室参数。
主要发现
- RBCx后溶血参数和贫血改善,但左心室容积指数轻度增加。
- HSCT后3个月心脏大小、功能和舒张充盈参数显著改善,此后至1年继续较小改善。
- HSCT后1年NT-proBNP水平显著改善,6分钟步行时间有改善趋势。
- HSCT后心脏改善幅度与妊娠或慢性瓣膜反流修复后容量超负荷纠正所观察到的改善相当。
临床怎么用
- HSCT可逆转镰状细胞病相关的心脏结构及功能异常,支持对合并心脏并发症的患者评估HSCT指征。
局限性
- 需进一步研究明确镰状细胞病中哪些心脏并发症及严重程度应视为HSCT指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiac complications have been well-described in sickle cell disease; however, it has been rare to see improvements in cardiac abnormalities following any interventions. Previous work has shown no significant structural changes after treatment with hydroxyurea. The cardiac effects of red blood cell exchange transfusion (RBCx) and hematopoietic stem cell transplantation (HSCT) have not been well described. We studied 56 patients undergoing HSCT (41 HLA-matched, 15 haploidentical), of whom 32 had RBCx within 3 months before HSCT. Echocardiograms and laboratory parameters were obtained at baseline, and at 3, 6, and 12 months following HSCT. Although hemolytic parameters and anemia improved following RBCx, there was a small increase in left ventricular volume index. Following successful HSCT, however, there were significant improvements in cardiac size, function, and diastolic filling parameters at 3 months followed by continued smaller improvements up to 1 year. There was a significant improvement in N-terminal pro B-type natriuretic peptide levels and a trend toward improvement in 6-minute walk time 1 year after HSCT. The magnitude of cardiac improvement seen following HSCT was comparable to that observed following correction of a volume overload state as seen in pregnancy or after repair of chronic valvular regurgitation. Further studies in sickle cell disease patients will help delineate which cardiac complications and what level of severity should be considered indications for HSCT.
引用
- Sachdev V, Hsieh M, Jeffries N, et al. Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2019. PMID: 31578191. doi:10.1182/bloodadvances.2019000387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。